Pharma Mar S.A.
ISIN: ES0169501022 | Ticker: PHM | LEI: 959800QWKZ45ZQC2AV58
Country: Spain
PharmaMar is a fully integrated Spanish biotech/pharmaceutical. Born in 1986, the company takes its inspiration for discovery of oncology medicines from the sea.
We are inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. We intend to continue to be the world leader in marine medicinal discovery, development and innovation.
90% of all drugs entering clinical trials fail to gain approval. With a first approval in 2007, and a third drug approved by 2020, our hypothesis and platform technology have been validated. To get 3 drugs approved is something under 1% of biotech companies achieve. We are in the 1%.
1986
Served areaWorldwide
Headcount477
HeadquartersAV/ de los Reyes 1, 28770 Colmenar – Spain
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 124,705,000.00 | 330,259,000.00 | 368,386,000.00 | 393,259,000.00 |
| Noncurrent Assets | N/A | 74,729,000.00 | 84,608,000.00 | 73,155,000.00 | 118,076,000.00 |
| Property Plant And Equipment | N/A | 22,452,000.00 | 21,947,000.00 | 26,961,000.00 | 31,163,000.00 |
| Investment Property | N/A | 845,000.00 | 845,000.00 | 845,000.00 | 845,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 6,074,000.00 | 3,860,000.00 | 3,233,000.00 | 2,589,000.00 |
| Deferred Tax Assets | N/A | 40,984,000.00 | 33,416,000.00 | 27,750,000.00 | 30,529,000.00 |
| Other Noncurrent Financial Assets | N/A | 1,029,000.00 | 20,988,000.00 | 10,722,000.00 | 49,398,000.00 |
| Current Assets | N/A | 49,976,000.00 | 245,651,000.00 | 295,231,000.00 | 275,183,000.00 |
| Inventories | N/A | 8,902,000.00 | 11,933,000.00 | 10,536,000.00 | 27,746,000.00 |
| Trade And Other Current Receivables | N/A | 11,530,000.00 | 24,054,000.00 | 50,908,000.00 | 29,328,000.00 |
| Other Current Financial Assets | N/A | 8,649,000.00 | 14,148,000.00 | 31,907,000.00 | 35,689,000.00 |
| Current Financial Assets At Amortised Cost | N/A | 3,257,000.00 | 99,306,000.00 | 88,532,000.00 | 32,607,000.00 |
| Cash and cash equivalents | 22,745,000.00 | 17,638,000.00 | 96,210,000.00 | 113,348,000.00 | 149,813,000.00 |
| Equity And Liabilities | N/A | 124,705,000.00 | 330,259,000.00 | 368,386,000.00 | 393,259,000.00 |
| Equity | 17,473,000.00 | 7,456,000.00 | 102,722,000.00 | 177,918,000.00 | 222,957,000.00 |
| Issued Capital | N/A | 11,132,000.00 | 11,013,000.00 | 11,013,000.00 | 11,013,000.00 |
| Share Premium | N/A | 71,278,000.00 | 71,278,000.00 | 71,278,000.00 | 71,278,000.00 |
| Treasury Shares | N/A | 1,499,000.00 | 21,453,000.00 | 25,679,000.00 | 15,865,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 11,374,000.00 | 102,722,000.00 | 177,918,000.00 | 222,957,000.00 |
| Noncontrolling Interests | N/A | -3,918,000.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | N/A | 117,249,000.00 | 227,537,000.00 | 190,468,000.00 | 170,302,000.00 |
| Noncurrent Liabilities | N/A | 56,810,000.00 | 132,618,000.00 | 104,122,000.00 | 72,982,000.00 |
| Other Noncurrent Liabilities | N/A | 177,000.00 | 176,000.00 | 186,000.00 | 186,000.00 |
| Current Liabilities | N/A | 60,439,000.00 | 94,919,000.00 | 86,346,000.00 | 97,320,000.00 |
| Trade And Other Current Payables | N/A | 19,332,000.00 | 23,220,000.00 | 29,269,000.00 | 29,959,000.00 |
| Other Current Liabilities | N/A | 2,575,000.00 | 4,902,000.00 | 5,833,000.00 | 19,359,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue From Royalties | 3,102,000.00 | 15,661,000.00 | 40,996,000.00 | 50,254,000.00 |
| Revenue From Contracts With Customers | 85,819,000.00 | 269,961,000.00 | 229,831,000.00 | 196,343,000.00 |
| Other Gains Losses | 966,000.00 | 1,108,000.00 | 1,794,000.00 | 3,601,000.00 |
| Profit Loss From Operating Activities | -17,486,000.00 | 155,944,000.00 | 92,447,000.00 | 44,071,000.00 |
| Finance Income | 203,000.00 | 5,038,000.00 | 10,365,000.00 | 11,006,000.00 |
| Finance Costs | 4,371,000.00 | 15,376,000.00 | 7,683,000.00 | 11,287,000.00 |
| Profit Loss Before Tax | -21,654,000.00 | 145,606,000.00 | 95,129,000.00 | 43,790,000.00 |
| Income Tax Expense Continuing Operations | -12,474,000.00 | 8,344,000.00 | 2,270,000.00 | -5,566,000.00 |
| Profit Loss From Continuing Operations | -9,180,000.00 | 137,262,000.00 | N/A | N/A |
| Profit Loss From Discontinued Operations | -2,217,000.00 | 0.00 | N/A | N/A |
| Profit (loss) | -11,397,000.00 | 137,262,000.00 | 92,859,000.00 | 49,356,000.00 |
| Profit Loss Attributable To Owners Of Parent | -11,379,000.00 | 137,262,000.00 | 92,859,000.00 | 49,356,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | -18,000.00 | 0.00 | N/A | N/A |
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | -11,397,000.00 | 137,262,000.00 | 92,859,000.00 | 49,356,000.00 |
| Adjustments For Finance Costs | N/A | 3,753,000.00 | 3,124,000.00 | 3,373,000.00 | 2,376,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 2,418,000.00 | 3,031,000.00 | -1,398,000.00 | 17,210,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -5,499,000.00 | -4,654,000.00 | -7,185,000.00 | -1,786,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 8,034,000.00 | 7,211,000.00 | 5,583,000.00 | 5,900,000.00 |
| Adjustments For Provisions | N/A | N/A | N/A | -93,000.00 | 15,083,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 0.00 | 7,550,000.00 | -5,674,000.00 | -3,108,000.00 |
| Adjustments For Sharebased Payments | N/A | 265,000.00 | 274,000.00 | 339,000.00 | 393,000.00 |
| Other Adjustments To Reconcile Profit Loss | N/A | 29,000.00 | 0.00 | 0.00 | -22,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 2,321,000.00 | 3,124,000.00 | 3,373,000.00 | 2,376,000.00 |
| Interest Received Classified As Operating Activities | N/A | 35,000.00 | 336,000.00 | 370,000.00 | 875,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 9,650,000.00 | 7,863,000.00 | -2,720,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -24,209,000.00 | 278,942,000.00 | 25,677,000.00 | 38,321,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 33,386,000.00 | 0.00 | N/A | N/A |
| Other Inflows Outflows Of Cash Classified As Investing Activities | N/A | 2,637,000.00 | 0.00 | 26,275,000.00 | 238,918,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 32,068,000.00 | -119,009,000.00 | 18,472,000.00 | 10,878,000.00 |
| Proceeds From Issuing Shares | N/A | -14,000.00 | 0.00 | N/A | N/A |
| Proceeds From Issuing Other Equity Instruments | N/A | 8,564,000.00 | 30,366,000.00 | 33,554,000.00 | 57,227,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 7,467,000.00 | 63,708,000.00 | 40,659,000.00 | 50,178,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 4,792,000.00 | 834,000.00 | 5,832,000.00 | 1,543,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 18,841,000.00 | 32,373,000.00 | 15,270,000.00 | 10,201,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 0.00 | 8,819,000.00 | 10,872,000.00 | 11,761,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -12,966,000.00 | -73,820,000.00 | -27,415,000.00 | -13,370,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | -7,541,000.00 | 404,000.00 | 636,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -5,107,000.00 | 78,572,000.00 | 17,138,000.00 | 36,465,000.00 |
| Cash and cash equivalents | 22,745,000.00 | 17,638,000.00 | 96,210,000.00 | 113,348,000.00 | 149,813,000.00 |
Please note that some sums might not add up.
ES0169501022
LEI959800QWKZ45ZQC2AV58
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.